Dr Reddy's application for biosimilar candidate accepted for review by USFDA

Rituximab is used to treat certain autoimmune diseases and types of cancer. "This milestone underscores our capability for global clinical development of high-quality biosimilar products for highly regulated and global markets," Dr Reddy's Global Head of Biologics Jayanth Sridhar said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P4Lw6qV
via IFTTT